JP2017535567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535567A5 JP2017535567A5 JP2017527366A JP2017527366A JP2017535567A5 JP 2017535567 A5 JP2017535567 A5 JP 2017535567A5 JP 2017527366 A JP2017527366 A JP 2017527366A JP 2017527366 A JP2017527366 A JP 2017527366A JP 2017535567 A5 JP2017535567 A5 JP 2017535567A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- alpha
- desmopressin
- adrenergic receptor
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 17
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims 10
- 229960004281 desmopressin Drugs 0.000 claims 10
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims 10
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 8
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 8
- 239000000674 adrenergic antagonist Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims 2
- QZHXKQKKEBXYRG-UHFFFAOYSA-N 4-n-(4-aminophenyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NC1=CC=C(N)C=C1 QZHXKQKKEBXYRG-UHFFFAOYSA-N 0.000 claims 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 2
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims 2
- 229960004607 alfuzosin Drugs 0.000 claims 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims 2
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 claims 2
- 229950010351 amosulalol Drugs 0.000 claims 2
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 claims 2
- 229950010731 arotinolol Drugs 0.000 claims 2
- HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 claims 2
- 229960003002 atipamezole Drugs 0.000 claims 2
- RFWZESUMWJKKRN-UHFFFAOYSA-N dapiprazole Chemical compound CC1=CC=CC=C1N1CCN(CCC=2N3CCCCC3=NN=2)CC1 RFWZESUMWJKKRN-UHFFFAOYSA-N 0.000 claims 2
- 229960002947 dapiprazole Drugs 0.000 claims 2
- 229960001389 doxazosin Drugs 0.000 claims 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- FQHMMOGHDWAXDI-WUQHHHCFSA-N ergoloid mesylate Chemical compound CS(O)(=O)=O.C([C@H]1[C@]2(O)O3)CCN1C(=O)[C@H](C)N2C(=O)[C@]3(C(C)C)NC(=O)[C@H]1CN(C)[C@H](CC=2C3=C4C=CC=C3NC=2)[C@@H]4C1 FQHMMOGHDWAXDI-WUQHHHCFSA-N 0.000 claims 2
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 claims 2
- 229950001476 idazoxan Drugs 0.000 claims 2
- 229960001632 labetalol Drugs 0.000 claims 2
- 210000002200 mouth mucosa Anatomy 0.000 claims 2
- -1 naphthopidyl Chemical compound 0.000 claims 2
- 210000002850 nasal mucosa Anatomy 0.000 claims 2
- 229960003642 nicergoline Drugs 0.000 claims 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001999 phentolamine Drugs 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229960001289 prazosin Drugs 0.000 claims 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 2
- 229960004953 silodosin Drugs 0.000 claims 2
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 claims 2
- 229960002613 tamsulosin Drugs 0.000 claims 2
- 229960001693 terazosin Drugs 0.000 claims 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- SNEPAAKJPPNOQM-UHFFFAOYSA-N 4,8-dimethyl-1,2,5,6-tetrahydrobenzo[f]quinolizin-3-one Chemical compound C1CC2=CC(C)=CC=C2N2C1=C(C)C(=O)CC2 SNEPAAKJPPNOQM-UHFFFAOYSA-N 0.000 claims 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 1
- 108060003345 Adrenergic Receptor Proteins 0.000 claims 1
- 102000017910 Adrenergic receptor Human genes 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 claims 1
- VMGWGDPZHXPFTC-HYBUGGRVSA-N Izonsteride Chemical compound CN([C@@H]1CCC2=C3)C(=O)CC[C@]1(C)C2=CC=C3SC(S1)=NC2=C1C=CC=C2CC VMGWGDPZHXPFTC-HYBUGGRVSA-N 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004199 dutasteride Drugs 0.000 claims 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical group O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims 1
- 229950009537 epristeride Drugs 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 229950004319 izonsteride Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 claims 1
- 229950007816 turosteride Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082301P | 2014-11-20 | 2014-11-20 | |
| US62/082,301 | 2014-11-20 | ||
| PCT/US2015/061686 WO2016081772A1 (en) | 2014-11-20 | 2015-11-19 | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020037385A Division JP2020097632A (ja) | 2014-11-20 | 2020-03-05 | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535567A JP2017535567A (ja) | 2017-11-30 |
| JP2017535567A5 true JP2017535567A5 (enExample) | 2018-12-27 |
Family
ID=54784026
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527366A Pending JP2017535567A (ja) | 2014-11-20 | 2015-11-19 | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2020037385A Withdrawn JP2020097632A (ja) | 2014-11-20 | 2020-03-05 | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2022069213A Pending JP2022095948A (ja) | 2014-11-20 | 2022-04-20 | アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2024134846A Pending JP2024161452A (ja) | 2014-11-20 | 2024-08-13 | アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020037385A Withdrawn JP2020097632A (ja) | 2014-11-20 | 2020-03-05 | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2022069213A Pending JP2022095948A (ja) | 2014-11-20 | 2022-04-20 | アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| JP2024134846A Pending JP2024161452A (ja) | 2014-11-20 | 2024-08-13 | アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10286033B2 (enExample) |
| EP (1) | EP3220942B1 (enExample) |
| JP (4) | JP2017535567A (enExample) |
| KR (2) | KR20240010751A (enExample) |
| CN (1) | CN106999538A (enExample) |
| AU (1) | AU2015349811B2 (enExample) |
| CA (1) | CA2967390A1 (enExample) |
| DK (1) | DK3220942T3 (enExample) |
| ES (1) | ES2923438T3 (enExample) |
| MX (1) | MX2017006655A (enExample) |
| WO (1) | WO2016081772A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| US12214010B2 (en) * | 2023-04-04 | 2025-02-04 | Tulex Pharmaceuticals Inc. | Desmopressin oral compositions |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| NZ241979A (en) | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| CA2312839C (en) * | 1997-12-02 | 2008-01-15 | Lisbeth Illum | Compositions for nasal administration |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| AT409081B (de) * | 2000-02-16 | 2002-05-27 | Gebro Pharma Gmbh | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung |
| WO2002055128A2 (en) | 2000-11-30 | 2002-07-18 | Biovalve Technologies Inc | Fluid delivery and measurement systems and methods |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| US20030060513A1 (en) * | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| AU2003284700B2 (en) | 2002-11-07 | 2009-05-28 | Astellas Pharma Inc. | Remedy for overactive bladder comprising acetic acid anlide derivatives as the active ingredient |
| JP5596252B2 (ja) * | 2003-11-10 | 2014-09-24 | アラーガン、インコーポレイテッド | 低用量デスモプレシンを含有する医薬組成物 |
| KR100978717B1 (ko) | 2003-12-08 | 2010-08-30 | 씨펙스 파마슈티칼스, 인코포레이티드 | 인슐린 치료를 위한 약제 조성물 및 방법 |
| DE102005016981A1 (de) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| WO2007072156A1 (en) | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
| WO2007083640A1 (ja) | 2006-01-18 | 2007-07-26 | Kyorin Pharmaceutical Co., Ltd. | 頻尿及び尿失禁の予防又は治療剤 |
| NZ572065A (en) * | 2006-04-21 | 2012-03-30 | Toko Yakuhin Kogyo Kk | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
| AU2008283929B2 (en) * | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| CN101648017A (zh) * | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| US20110144055A1 (en) * | 2008-09-04 | 2011-06-16 | Rozmanith Anthony I | Health Care |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| PL2381923T5 (pl) | 2008-12-22 | 2024-08-26 | Acerus Pharmaceuticals USA, LLC | Donosowe podawanie desmopresyny |
| EP3278809B1 (en) * | 2009-06-18 | 2019-11-20 | Serenity Pharmaceuticals LLC | Safe desmopressin administration |
| CA2774992A1 (en) | 2009-10-07 | 2011-04-14 | Merck Sharp & Dohme Corp. | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
| US9119878B2 (en) * | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| EP2672958A1 (en) * | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| CN107569690A (zh) * | 2012-01-04 | 2018-01-12 | 韦尔斯利医药有限公司 | 用于缓解尿频的延长释放制剂及其使用方法 |
| CN107157991A (zh) * | 2012-03-19 | 2017-09-15 | 韦尔斯利医药有限公司 | 用于缓解尿频的延长释放制剂及其使用方法 |
| TW201422254A (zh) * | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| KR20210103590A (ko) * | 2013-07-23 | 2021-08-23 | 세레니티 파마슈티컬즈 엘엘씨 | 5-알파 환원효소 억제제와 함께 데스모프레신을 포함하는 방법 및 조성물 |
| MX2016001030A (es) | 2013-07-23 | 2016-10-07 | Allergan Inc | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
| EP3041461A4 (en) * | 2013-09-03 | 2017-05-03 | G2B Pharma Inc. | Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions |
| JP2014177491A (ja) * | 2014-06-26 | 2014-09-25 | Allergan Inc | 低用量デスモプレシンを含有する医薬組成物 |
-
2015
- 2015-11-19 WO PCT/US2015/061686 patent/WO2016081772A1/en not_active Ceased
- 2015-11-19 AU AU2015349811A patent/AU2015349811B2/en not_active Ceased
- 2015-11-19 ES ES15805360T patent/ES2923438T3/es active Active
- 2015-11-19 EP EP15805360.3A patent/EP3220942B1/en not_active Not-in-force
- 2015-11-19 KR KR1020247000547A patent/KR20240010751A/ko not_active Ceased
- 2015-11-19 US US15/528,224 patent/US10286033B2/en active Active
- 2015-11-19 MX MX2017006655A patent/MX2017006655A/es unknown
- 2015-11-19 CA CA2967390A patent/CA2967390A1/en active Pending
- 2015-11-19 CN CN201580062683.6A patent/CN106999538A/zh active Pending
- 2015-11-19 KR KR1020177016896A patent/KR20170097045A/ko not_active Ceased
- 2015-11-19 JP JP2017527366A patent/JP2017535567A/ja active Pending
- 2015-11-19 DK DK15805360.3T patent/DK3220942T3/da active
-
2020
- 2020-03-05 JP JP2020037385A patent/JP2020097632A/ja not_active Withdrawn
-
2022
- 2022-04-20 JP JP2022069213A patent/JP2022095948A/ja active Pending
-
2024
- 2024-08-13 JP JP2024134846A patent/JP2024161452A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Minkowitz et al. | Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain | |
| Davies et al. | Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain | |
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| CN109640981A (zh) | 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途 | |
| EA201270041A1 (ru) | Лечение рассеянного склероза лаквинимодом | |
| ES2970059T3 (es) | Método de tratamiento del síndrome de Prader-Willi | |
| JP2017506624A5 (enExample) | ||
| Landwehr et al. | A comparison between IV paracetamol and IV metamizol for postoperative analgesia after retinal surgery | |
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| JP2020503269A5 (enExample) | ||
| MY205229A (en) | Oral dosage form with drug composition, barrier layer and drug layer | |
| JP2020500864A5 (enExample) | ||
| CN118078835A (zh) | 用于夜间尿频的治疗剂 | |
| JP2016505561A5 (enExample) | ||
| JP2017535567A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| JP2013510841A5 (enExample) | ||
| RU2012124038A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
| MX2023002649A (es) | Nueva formulacion de acido gamma-aminobutirico. | |
| MX2015010594A (es) | Esteres de testosterona de cadena larga lipobalanceados para suministro oral. | |
| JP2019533672A5 (enExample) | ||
| KR20180074707A (ko) | 저 용량 경구 디피리다몰 조성물 및 이의 용도 | |
| ES2957232T3 (es) | Composiciones para el tratamiento o la prevención de síntomas vasomotores |